Research programme: type 1 diabetes therapy - JDRF/Novartis
Latest Information Update: 11 Aug 2009
At a glance
- Originator JDRF; Novartis
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Type 1 diabetes mellitus
Most Recent Events
- 05 Aug 2009 Investigation in Type-1 diabetes mellitus in USA (unspecified route)